Bone Marrow Transplant

• 

  Publication Venue For

  • Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation..  54:1254-1265. 2019
  • Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation..  53:1278-1287. 2018
  • Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation..  53:1079-1082. 2018
  • Biomarkers in chronic graft-versus-host disease: quo vadis?.  53:832-837. 2018
  • Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation..  53:932-937. 2018
  • High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma..  53:34-38. 2018
  • Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2..  52:1575-1576. 2017
  • Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study..  52:1483-1484. 2017
  • Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma..  52:839-845. 2017
  • Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients..  52:580-587. 2017
  • Cognitive problems following hematopoietic stem cell transplant: relationships with sleep, depression and fatigue..  52:279-284. 2017
  • Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN..  51:1173-1179. 2016
  • Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors..  51:938-944. 2016
  • Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation..  51:999-1001. 2016
  • Personalized home-based interval exercise training may improve cardiorespiratory fitness in cancer patients preparing to undergo hematopoietic cell transplantation..  51:967-972. 2016
  • Regionalization of stem cell transplant procedures into teaching hospitals in United States: are we ready?.  51:1004-1006. 2016
  • Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD..  51:607-609. 2016
  • Prevalence, predictors and outcomes of cardiopulmonary resuscitation in hospitalized adult stem cell transplant recipients in the United States: not just opening the black box but exploring an opportunity to optimize!.  50:1578-1581. 2015
  • Umbilical cord blood donation: public or private?.  50:1271-1278. 2015
  • Important impact of gingival and periodontal conditions on outcomes in SCT recipients..  50:604-606. 2015
  • Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor..  50:197-203. 2015
  • Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study..  49:1330-1336. 2014
  • Outcomes of stem cell transplant patients with acute respiratory failure requiring mechanical ventilation in the United States..  49:1278-1286. 2014
  • Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone..  48:1444-1449. 2013
  • Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study..  48:1342-1349. 2013
  • Long-term outcome of non-ablative booster BMT in patients with SCID..  48:1050-1055. 2013
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment..  48:926-931. 2013
  • Rescuing the neonatal brain from hypoxic injury with autologous cord blood..  48:890-900. 2013
  • Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT..  48:771-776. 2013
  • Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia..  48:666-670. 2013
  • Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL..  48:26-31. 2013
  • A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up..  47:1448-1454. 2012
  • Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors..  47:1283-1286. 2012
  • Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial..  47:1350-1355. 2012
  • Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration..  47:1051-1055. 2012
  • Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors..  47:817-823. 2012
  • Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis..  47:810-816. 2012
  • Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation..  47:700-705. 2012
  • Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients..  47:352-359. 2012
  • Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma..  46:847-851. 2011
  • Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells..  45:379-384. 2010
  • Therapy with mycophenolate mofetil for refractory acute and chronic GVHD..  44:739-748. 2009
  • Umbilical cord blood transplantation for non-malignant diseases..  44:643-651. 2009
  • Fungal infection prevention after hematopoietic cell transplantation..  44:483-487. 2009
  • Auto-SCT for AML in second remission: CALGB study 9620..  44:353-359. 2009
  • Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study..  44:339-343. 2009
  • Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis..  44:387-389. 2009
  • Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience..  44:89-96. 2009
  • Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer..  44:81-87. 2009
  • A novel approach for quantification of KIR expression in healthy donors and pediatric recipients of hematopoietic SCTs..  43:525-532. 2009
  • Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors..  43:327-333. 2009